Radient Pharmaceuticals Corporation fka RXPC

[Future Doc]

Maybe they weren't aware of the better performance of the new antibodies until AFTER a comparison was made. A lot of times these things aren't known until AFTER trials with multiple antibodies are performed. According to research at the time of the development of the kit, they probably were under the impression that their original antibody was best suited for that purpose. Even with the most advanced modeling and binding site theory testing, certain things cannot be predicted until they are actually tested. Maybe this new antibody wasn't available until they made the new kit. I'm not exactly sure.

However, an antibody switch can certainly increase the specificity and sensitivity drastically. It is the main portion of the test. It is possible that the binding sites on this new antibody are more pure (less disfigured product per batch). Or it is possible that they are more specific for FDP (better FDP level detection). Or maybe they are less likely to bind other antigens (less false positives). All possibilities.